Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

Annals of Internal Medicine

Volumn 138, Issue 10, 2003, Pages

  Kwon, Hyon J ^a   Coté, Timothy R ^b   Cuffe, Michael S ^b   Kramer, Judith M ^b   Braun, M Miles ^b  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CASE REPORT; CLINICAL ARTICLE; CLINICAL FEATURE; CROHN DISEASE; DISEASE EXACERBATION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEMALE; FOOD AND DRUG ADMINISTRATION; HEART FAILURE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MALE; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; UNITED STATES; CHEMICALLY INDUCED DISORDER; CONGESTIVE HEART FAILURE; DRUG ANTAGONISM; MIDDLE AGED; ONSET AGE; REVIEW; RISK FACTOR;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGE OF ONSET; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CROHN DISEASE; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0037672879     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-138-10-200305200-00008     Document Type: Article

References (16)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-41. [PMID: 2195340]
2. Torre-Amione G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-6. [PMID: 8609343]
3. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ Res. 1997;81:627-35. [PMID: 9314845]
4. Bryant D, Becker L, Richardson J, Shelton J, Franco F, Peshock R, et al. Cardiac failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha. Circulation. 1998;97:1375-81. [PMID: 9577949]
5. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet, 1998;351:1091-3. [PMID: 9660578]
6. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224-6. [PMID: 10385494]
7. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (ENBREL) in patients with advanced heart failure. Circulation. 2001;103: 1044-7. [PMID: 11222463]
8. Louis A, Cleland JG, Crabbe S, Ford S, Thackray S, Houghton T, et al. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail. 2001;3:381-7. [PMID: 11378012]
9. Dear Healthcare Professional [Letter]. Malvern, PA: Centocor; 23 October 2001.
10. Cush JJ, Matteson EL, eds. FDA Advisory Committee Reviews Safety of TNF Inhibitors. Accessed at www.rheumatology.org/research/hotline/0901tnf .html on 7 November 2001.
11. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269: 2765-8. [PMID: 8492403]
12. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824-9. [PMID: 10071004]
13. Feldman AM, Combes A, Wagner D, Kadakomi T, Kubota T, Li YY, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol. 2000;35:537-44. [PMID: 10716453]
14. European Society of Cardiology's Heart Failure Update. RENEWAL trial: no improvement in CHF with etanercept. Accessed at www.theheart.org/documents /page.cfm?from = 590001200&doc_id = 3053 on 10 July 2002.
15. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis. 2000;59:321-5. [PMID: 10784507]
16. Congestive Heart Failure in the United States: A New Epidemic. National Heart, Lung, and Blood Institute Data Fact Sheet. Accessed at www.nhlbi.nih .gov/health/public/heart/other/CHF.htm on 7 November 2001.